Xact Kapitalforvaltning’s Blueprint Medicines BPMC Stock Holding History

Xact Kapitalforvaltning’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$442K	Hold	7,551	–	–	0.01%	823
2019 Q4	$605K	Hold	7,551	–	–	0.01%	855
2019 Q3	$555K	Hold	7,551	–	–	0.01%	859
2019 Q2	$712K	Buy	7,551 +1,100	+17%	+$90.8K	0.01%	726
2019 Q1	$516K	Sell	6,451 -300	-4%	-$22.2K	0.01%	899
2018 Q4	$364K	Hold	6,751	–	–	0.01%	1111
2018 Q3	$527K	Buy	6,751 +600	+10%	+$41.7K	0.01%	932
2018 Q2	$390K	Buy	6,151 +800	+15%	+$63.7K	0.01%	1130
2018 Q1	$491K	Buy	5,351 +1,500	+39%	+$129K	0.01%	841
2017 Q4	$290K	Buy	+3,851	New	+$271K	0.01%	972

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Xact Kapitalforvaltning's BPMC Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Blueprint Medicines (BPMC) position steady in Q1 2020 at 7,551 shares worth $442K. The position accounts for 0.01% of the portfolio, ranked #823.

Xact Kapitalforvaltning first reported a position in BPMC in Q4 2017 and has held it in 10 quarters since. The position peaked at $712K in Q2 2019. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

Xact Kapitalforvaltning held 7,551 shares of Blueprint Medicines worth $442K as of Q1 2020.
Xact Kapitalforvaltning left its Blueprint Medicines share count unchanged in Q1 2020.
Blueprint Medicines made up 0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #823 holding.
Xact Kapitalforvaltning first reported a position in Blueprint Medicines in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Blueprint Medicines position peaked at $712K in Q2 2019.
214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.